Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellumen, a discovery toxicology company, has appointed Jack Reynolds, former executive of Pfizer, to its board of directors.
Subscribe to our email newsletter
With more than 30 years of experience in the pharmaceutical industry, Dr Reynolds is founder and principal at JAReynolds & Associates.
Prior to his current role, Dr Reynolds worked at Pfizer Global R&D for nearly 20 years, where he served as senior vice president of R&D and was head of worldwide safety sciences and comparative medicine.
Lansing Taylor, CEO of Cellumen, said: “We are incredibly pleased to welcome Jack to our team. He is highly regarded for his work in early safety testing, and we are confident that he will serve as a trusted advisor for the team at Cellumen, helping us to continue identifying safety liabilities earlier in the drug development process.”